AML cells with normal karyotype (NK) and wild type status of TP53 with elevated FLT3 and MDM2 protein levels emerge to be susceptible to the combined treatment with the MEK1 inhibitor cobimetinib and the MDM2 inhibitor idasanutlin. This evidence concerns the gene MAP2K1 and acute myeloid leukemia.